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Lithium treatment reduces the renal kallikrein excretion rate. Lithium
salts are widely used agents for the prophylactic treatment of affective
disorders. Lithium salts may be associated with distal nephron dysfunc-
tion. Kallikrein is a protease which is generated by the distal nephron.
We used an amidolytic assay of chromatographically purified enzyme to
determine the urinary excretion rate of active kallikrein in relation to
lithium treatment. All plasma lithium concentrations were within the
therapeutic range (0.4 to 0.9 mmol/liter). In 15 patients the urinary
excretion rate of active kallikrein was 267.4 65.6 mU/24 hrs before
lithium treatment, and fell to 117.8 39.6 mU/24 hrs (P < 0.05) on day
14 of lithium treatment. This reduction was associated with a decrease
of immunoreactive kallikrein in the same urines by 66%. In another 15
patients who had undergone lithium therapy for an average period of 5.6
years, the urinary excretion rate of active kallikrein was 86.1 14.5
mUI24 hrs, while 21 age-matched healthy controls had an excretion rate
of 364.1 58.4 mU/24 hrs (P < 0.05). Measurements of immunoreac-
tive kallikrein in the same urine samples demonstrated a reduction of
kallikrein after long-term lithium treatment by 78%. These observations
could not be attributed to changes in creatinine clearance, renal sodium
or potassium excretion rates or plasma concentrations of aldosterone
and vasopressin. Addition of lithium to the urine in vitro had no
demonstrable effect on kallikrein measurement by amidolytic assay. We
conclude that lithium in therapeutic plasma concentrations may directly
suppress the secretion of kallikrein by renal connecting tubule cells.
The effectiveness of lithium as a prophylactic treatment of
affective disorders is well established [1]. The large number of
patients afflicted and the necessity to prescribe lithium treat-
ment over prolonged periods—often involving many years [1,
2]—has raised concern about potential side-effects of this
medication [3]. In the kidney adverse effects may occur at
therapeutic plasma levels of lithium. They include nephrogenic
diabetes insipidus [4], defective distal tubular acidification [5]
and others [3]. In addition, renal morphological changes have
been observed in distal tubular, connecting tubular and collect-
ing duct epithelia [6-12]. Taken together, these observations
indicate a preferential involvement of the distal nephron in
those adverse effects.
Kallikrein is an enzyme which may generate kinins [13]. In
the kidney kallikrein is produced and released by connecting
tubular epithelial cells of the distal nephron [13—16]. We were
intrigued by the close spatial relationship between the site of
Received for publication October 12, 1989
and in revised form February 9, 1990
Accepted for publication February 13, 1990
© 1990 by the International Society of Nephrology
kallikrein release and the localization of functional and morpho-
logical changes observed after lithium in the kidney. We asked
the question whether lithium treatment might also affect renal
kallikrein.
Methods
Patients
To test the effects of short-term and long-term lithium treat-
ment the urinary excretion rate of kallikrein was measured in
several groups of patients:
a) In 15 patients suffering from a DSM-III affective disorder
(manic depressive disorder) [17], who had never received lith-
ium before. They were consecutive admissions to the Depart-
ment of Psychiatry of the University of Heidelberg. Measure-
ments were obtained just prior to the beginning of lithium
therapy and then again on day 14 of such treatment.
b) In 15 randomly-selected patients who had previously
received continuous lithium treatment of an affective disorder
for at least one year. All of these patients were cared for by the
out-patient clinic of the Department of Psychiatry of the Uni-
versity of Heidelberg.
c) Measurements were simultaneously obtained in 21 age-
matched healthy volunteers serving as controls. A plasma
lithium concentration of 0.4 to 0.9 mmollliter is considered
therapeutic at our institution; patients included in our study did
not exceed this range of concentrations. In all instances lithium
therapy had been recommended by the psychiatrists in charge
of the patient. All patients had given prior consent to the
procedures of the study.
Protocol of evaluation
When a patient was entered into the study, we obtained a
history, a complete physical examination and a standardized
blood sample at rest. We documented the present symptoms,
the indications for lithium treatment, the current medication
and any historical evidence of recent dehydration. In the
physical examination, we searched for signs of dehydration or
plasma volume contraction. All blood samples were drawn at
about 3 p.m.; patients were not fasting. After placement of a
short indwelling catheter into a forearm vein, the patient rested
supine for 40 minutes. A 14 cc blood sample was drawn,
immediately partitioned into the appropriate iced tubes, placed
on ice and rapidly centrifuged at 3°C, at 4,800 x g for 10
minutes. The following parameters were measured: electrolytes
including lithium, magnesium and calcium; creatinine, urea and
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urate; total protein and albumin; osmolality; plasma renin
activity (PRA); aldosterone and antidiuretic hormone (ADH).
Urine samples. All measurements were based on the consec-
utive collection of two 24-hour urine specimens. These speci-
mens were pooled and submitted for measurements thereafter.
Specific precautions were taken to ensure completeness of
collection. While the collection was in progress, urine samples
were kept in a refrigerator at 3°C. The following parameters
were determined: urinary volume; osmolality; creatinine clear-
ance; electrolytes including magnesium and phosphate; the
kallikrein excretion rate was determined by amidolytic assay
and by radioimmunoassay (RIA).
Laboratory procedures
Osmolality (normal range: 280 to 300 mOsm/kg H20) was
measured by freezing point depression on an Osmomat 030
(Gonotec GmbH, Berlin, FRG) as described [18]; sodium,
potassium and lithium concentrations (recommended range of
lithium: 0.4 to 0.9 mmollliter) were determined by flame pho-
tometry (Beckman Instruments, Munich, FRG); creatinine,
urea (normal range: 15 to 45 mgldl), urate (normal range: 2.0 to
7.0 mg/dl), calcium, albumin and total protein concentrations by
autoanalyzer (Technicon, Dublin, Ireland, UK); magnesium
concentration by atomic absorption spectrophotometry (Perkin
Elmer, model 290, Uberlingen, FRG). The plasma aldosterone
concentration (normal range: 2.0 to 10.0 ng/dl) was determined
by RIA [19]; PRA by the method of Haber et a! with minor
modifications (range of normal results at rest: 0.3 to 2.0 ng
AIIm! x hr) [20]; ADH by RIA as described [21] (the mean
plasma ADH concentration in 20 adult volunteers by this assay
was 2.9 1.0 pg/mI).
Specific measurements
The amidolytic assay of kallikrein was based on previously
described methods [22—27]. In short, aliquots of thawed urine
were dialyzed against distilled water for 24 hours. This was
followed by dialysis against a phosphate-buffered (10 mM, pH
7.0) KC1 solution for an additional 24 hours. Dialyzed urine
samples were passed through columns containing DEAE-
SEPHADEX A-SO (Pharmacia Fine Chemicals, Freiburg,
FRG), 4 cc per column. Kallikrein was eluted with phosphate-
buffered KCI solution (700 mats of KC1) after rinsing with 200
mM KC1. No correction was made for losses. Amidolytic
activity was determined by incubating 400 sl of eluate with 0.15
mM D-VAL-LEU-ARG-PARANITROANILIDE (S 2266, Kabi
Diagnostica GmbH, Munich, FRG) and 500 s1 of TRIS-HCI (pH
8.2; 0.2 molJliter). Incubation was maintained for 30 minutes at
37°C, after which the reaction was stopped by addition of 100 p1
of 50% acetic acid. The enzymatic cleavage of S 2266, yielding
p-nitroaniline, attributable to the enzymatic activity of kal-
likrein was measured photometrically (Perkin Elmer 550 A, Oak
Brook, Illinois, USA) at 405 nm against a blank. Results of
measurements are reported in units (U); one unit is the amount
of enzyme capable of cleaving one mo1 of S 2266 per minute at
37°C. The range of normal values for urinary kallikrein deter-
mined by this assay is reported by our laboratory as 310 to 420
mU/24 hrs.
Table 1. Measurements of plasma and urinary parameters before and
after 14 days of lithium therapy in 15 patients with manic depressive
disorder (DSM-III affective disorder)
Parameter
Before
lithium
After 14
days of
lithium P
Measurements in plasma
Lithium concentration — 0.81 0.01
mM/liter
Urea concentration 29.0 2.4 30.0 1.8 NS
mg/d!
Urate concentration 4.6 0,2 4.8 0.3 NS
mg/di
Osmotality mOsm/kg 293.0 1.0 293.0 I.! NS
Aldosterone ngldi 10.0 1.3 9.1 2 NS
PRA ng Al/mi x hr 0.85 0.1 0.96 0.2 NS
ADH pg/mi 2.2 0.26 2.6 0.47 NS
Measurements in urine
Urinary volume 1/24 hr 1.9 0.2 1.8 0.2 NS
Clearance of creatinine 99.7 5.0 100 6.9 NS
mi/min/1.73 m2
Sodium excretion rate 169 22 162 19.9 NS
mM/24 hrs
Potassium excretion rate 70 4.2 81 11.1 NS
mM/24 hrs
The following parameters were also measured, but remained normal
and unaltered: a) plasma concentrations of sodium, potassium, calcium,
phosphate, magnesium, albumin and total protein; b) urinary excretion
rates of phosphate and osmoles.
Radioimmunoassay of kallikrein
The method used has been described in detail [28]. In the
assay an antibody against kallikrein raised in rabbits was used.
The lower limit of detection of kallikrein by this assay is 0.5
,sg/liter. The range of normal values of kallikrein measured by
this assay is reported by our laboratory as 60 to 100 g/24 hrs.
For measurements of kallikrein by RIA, which will be re-
ported in the subsequent section on results, we routinely
employed the same pretreatment of urine samples as described
above for amidolytic assay. However, in a subset of 12,
randomly-selected urine specimens, we also compared results
obtained by amidolytic assay as described above with those by
radioimmunoassay without urinary pretreatment. A significant
correlation of both measurements was found (N = 12; r = 0.89;
P < 0.0001).
Statistics
Results of measurements are reported as mean values SEM.
The Wilcoxon signed rank test was used for comparison be-
tween groups of data.
Results
General observations in short-term lithium treatment
In all 15 patients (women: 9, men: 6; mean age 39 years, range
18 to 67) a diagnosis of DSM-III affective disorder [17] had been
established. During the first 14 days of treatment plasma
concentrations of lithium were within the therapeutic range
(<0.9 mM; Table 1). Lithium therapy was associated with
transient diarrhea (2 patients) and increased thirst in one
patient. The dosages of additional psychiatric medications
remained unaltered throughout the study. Patients did not show
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Fig. 1. Urinary excretion rate of active kallikrein during lithium treat-
ment and control as determined by amidolytic activity of kallikrein.
<0.05
physical signs of dehydration or extracellular fluid volume
depletion. The body weight was 69.5 3.3 kg before and 69.9
4.1 kg on day 14 of lithium therapy (P = NS). Oral fluid intake
was 2.5 0.3 1/24 hrs before and 2.4 0.3 1/24 hrs on day 14
of lithium therapy (P NS). Upright mean arterial blood
pressure taken after three minutes of standing had a tendency to
increase (baseline: 90 4.5 mm Hg, day 14 of lithium therapy:
94.4 3.7 mm Hg), but the change was not significant (P <
0.09). Table I shows parameters which document hydration,
extracellular fluid volume status, creatinine clearance and po-
tential imbalances of renal electrolyte handling at the time of
kallikrein measurement. Osmolar clearance was 2.2 0.08
mi/mm at baseline and 2.2 0.09 on day 14 of lithium therapy
(P = NS); free water clearance at baseline was —0.86 0.07
mllmin, and on day 14 of lithium therapy was —0.97 0.08 (P
= NS). All of these data failed to demonstrate any abnormali-
ties or significant changes after the beginning of lithium treat-
ment.
General observations in long-term lithium treatment
The 15 patients (women: 6, men: 9; mean age 39 years, range
14 to 66) underwent an abbreviated evaluation primarily to
measure urinary kallikrein excretion. At the time of our study,
the average duration of lithium treatment had been 5.6 years.
Physical examination demonstrated normal hydration. The 24-
hour urinary volume was 2.1 0.3 liter. The serum lithium
concentration was 0.8 0.08 mM/liter. Serum electrolytes and
concentrations of urea and urate were all within normal limits;
the plasma creatinine concentration was 0.99 0.1 mg/dl,
which was normal. Urinary protein excretion rate was less than
200 mg/24 hrs in all.
Kallikrein in 24-hour urine samples
Short-term lithium treatment was associated with a signifi-
cant reduction of the excretion rate of active kallikrein (amido-
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Fig. 2. Urinary excretion rate of immunoreactive kallikrein in response
to lithium treatment and during control as determined by radioimmu-
noassay. < 0.05
lytic assay) by 56% (Fig. 1). This reduction was apparent as
early as 72 hours after the beginning of lithium treatment. Thus,
four randomly selected patients who collected urine samples at
72 hours after the beginning of lithium treatment had a reduced
excretion of active kallikrein of 117.4 77.8 mU/24 hrs (data
not shown in Fig. 1). Figure 1 also demonstrates comparable
findings in 15 patients who had undergone long-term lithium
treatment over several years. Results of measurements of
immunoreactive kallikrein are shown in Figure 2. The measure-
ments were performed on eluates from the same 24-hour urine
samples that had also been subjected to amidolytic assay
yielding the results reported in Figure 1. The set of observations
of active kallikrein (amidolytic assay, Fig. 1) closely resembled
the set of observations of immunoreactive kallikrein (Fig. 2).
When the results of both methods of measurement were ana-
lyzed by regression analysis they were significantly correlated(N = 66; r = 0.62; P < 0.00001).
Influence of lithium on amidolytic assay
Eight control urine samples were selected at random and
divided into two aliquots of equal volume. Lithium carbonate
was added to each second aliquot yielding a final concentration
of 5 mM/liter of lithium. Kallikrein activity was determined
subsequently in all 16 samples by a blinded observer. Kallikrein
was 412 9.1 mU in the eight samples without lithium addition
and 414 10.4 (P = NS) after pretreatment by lithium. Thus,
there was no difference between amidolytic measurements in
the presence or absence of lithium in urine samples.
Discussion
The urinary kallikrein excretion rate was found to be signif-
icantly reduced in association with lithium treatment. This
finding was demonstrated by two different methods of assay for
urinary kallikrein: the amidolytic assay of active kallikrein and
the radioimmunoassay. No attempts were made to measure
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inactive kallikrein by amidolytic assay after its activation. We
were able to exclude an interference between lithium and the
amidolytic assay. Reduced kallikrein excretion was consis-
tently present in different stages of lithium therapy. It could be
documented as early as 72 hrs after the beginning of lithium
therapy, as well as after 14 days and several years of such
therapy. Reduced kallikrein excretion occurred in patients that
had plasma lithium concentrations within the therapeutic range.
There was no evidence of renal insufficiency [29, 30] in these
patients. No changes of ADH [31], aldosterone [321, or potas-
sium and sodium output [33—34] were found that might have
contributed to the observed reduction of kallikrein excretion.
Therefore, we propose that lithium per se causes reduced renal
kallikrein excretion at low plasma concentrations. To our
knowledge this has not been reported before. However, as
documented in a recent preliminary report from our laboratory,
it was possible to reproduce the same finding in experimental
animals [35]. The latter observations indicated a reduced uri-
nary excretion rate of kallikrein along with a reduced renal
cortical content of kallikrein during lithium treatment in the rat.
Several renal side-effects of lithium have been reported. They
are: nephrogenic diabetes insipidus [4, 9, 36], reduced glomer-
ular filtration rate [37—39], hypercalcemia [40] and increased
excretion of sodium, potassium, calcium and phosphate by the
kidney [41—43]. None of these adverse effects were noted in the
patients of our study. Distal tubular acidification, which may
also be impaired [5, 44, 45], was not tested. Thus, our findings
do not clarify the relationship between the observed reduction
of kallikrein and the development of adverse effects of lithium
in the kidney. However, we were intrigued by findings in a
single patient with lithium intoxication—not mentioned in the
above—who had a plasma lithium concentration of 2.8 mM/liter,
urinary kallikrein concentration too low to be detectable by our
assay, and nonoliguric deterioration of renal function.
In future studies, the establishment of a relationship between
the plasma concentration of lithium and any renal side-effects of
this medication might be attempted. Conceivably, there could
be an order of increasing severity in renal side-effects, in which
reduced excretion of kallikrein might be an early event. In
addition, in such future studies, it may also be worthwhile to
test the effect of lithium—and thereby of reduced kallikrein—on
renal perfusion. If a relationship of this kind existed, it might
contribute to the understanding of renal lithium toxicity.
Acknowledgments
We are indebted to Professor W. Rascher, Department of Pediatrics,
University of Essen, Essen, FRG for performing measurements of
ADH; we are indebted to Professor E. Hackenthal, Department of
Pharmacology, University of Heidelberg, Heidelberg, FRG, for mea-
suring PRA.
Reprint requests to Dr. Peter Gross, Abteilung Innere Medizin und
Nephrologie, Klinikum Steglitz der Freien Universitäf Berlin, Hinden-
burgdamm 30, D-1000 Berlin 45, Federal Republic of Germany.
References
1. BAASTRUP PC, SCHOU M: Lithium as a prophylactic agent. Its
effect against recurrent depressions and manic depressive psycho-
sis. Arch Gen Psychiat 16:162—172, 1967
2. ANGST J, DITTRICH A, GROF P: Course of endogenous affective
psychoses and its modification by prophylactic administration of
imipramine and lithium. mt Pharmacopsychiat 2:1—11, 1969
3. SINGER I: Lithium and the kidney. Kidney mt 19:374—387, 1981
4. CHRISTENSEN SC, KUSANO E, YUSUFI ANK, MURAYAMA N,
DousA TP: Pathogenesis of nephrogenic diabetes insipidus due to
chronic administration of lithium in rats, J Clin Invest 75:1869—
1879, 1985
5. BATrLE D, GAvIRIA M, GRUPP M, ARRUDA JAL, WYNN J,
KURTZMAN NA: Distal nephron function in patients receiving
chronic lithium therapy. Kidney mt 21:477-485, 1982
6. HESTBECI-I J, HANSEN HE, AMDISEN A, OLSEN S: Chronic renal
lesions following long-term treatment with lithium. Kidney mt
12:205—213, 1977
7. MCAULIFFE WG, OLESEN OV: Effects of lithium on the structure
of the rat kidney. Nephron 34:114—124, 1983
8. JACOBSEN NO, OLESEN OV, THOMSEN K, OTTOSEN PD, OLSEN 5:
Early changes in renal distal convoluted tubules and collecting
ducts of lithium-treated rats. Lab Invest 46:298—305, 1982
9. HANSEN HE, HESTBECH J, SORENSEN JL, NORGAARD K, HElL-
SKOV J, AMDISEN A: Chronic interstitial nephropathy in patients on
long-term lithium treatment. Quart J Med 192:577—591, 1979
10. KLING MA, Fox JG, JOHNSTON SM, TOLKOFF-RUBIN NE, ROBIN
RH, COLVIN RB: Effects of long-term lithium administration on
renal Structure and function in rats. Lab Invest 50:526—535, 1984
11. WALKER RG, BENNETr WM, DAVIES BM, KINCAID-SMITH P:
Structural and functional effects of long-term lithium therapy.
Kidney mt (Suppl 11) 21:S13—Sl9, 1983
12. AURELL M, SVALANDER C, WALLIN L, ALLING C: Renal function
and biopsy findings in patients on long-term lithium treatment.
Kidney mt 20:663—670, 1981
13. ScicLi AG, CARRETERO OA: Renal kallikrein-kinin system. Kidney
mt 29:120—130, 1986
14. Vio CP, FIGUEROA CD: Subcellular localization of renal kallikrein
by ultrastructural immunocytochemistry. Kidney mt 28:36—42, 1985
15. BARAJAS L, POWERS K, CARRETERO 0, SCICLI AG, INAGAMI T:
Immunocytochemical localization of renin and kallikrein in the rat
renal cortex. Kidney Int 29:965—970, 1986
16. PROUD D, KNEPPER MA, PISANO JJ: Distribution of immunoreac-
tive kallikrein along the rat nephron. Am J Physiol 244:F520—F5l5,
1983
17. American Psychiatric Association: Diagnostic and Statistical Man-
ual of Mental Disorders (3rd ed). Washington D.C., APA, 1980
18. GROSS PA, PEHRISCH H, RASCHER W, SCHOMIG A, HACKENTHAL
E, RITZ E: Pathogenesis of clinical hyponatremia. EurJ Clin Invest
17:123—129, 1987
19. VECSEI P, GLESS KH: Aldosterone radioimmunoassay, in Aldoste-
rone Radioimmunoassay, edited by VEc5EI P, Stuttgart, Enke
Verlag, 1975
20. HABER E, KOERNER T, PAGE LB, KLEMAN B, PURNODE A:
Application of a RIA for angiotenSin Ito the physiologic measure-
ment of PRA in normal subjects. J Cliii Endocrinol Metab 29:
1349—1355, 1969
21. RASCHER W, LANG RE, UNGER T, GANTEN D, GROSS F: Vaso-
preSsin in brain of spontaneously hypertensive rats. Am J Physiol
242: H496—H499, 1982
22. BONNER G, MARIN-GREZ M: Measurement of kallikrein activity in
urine of rats and man using a chromogenic tripeptide substrate. J
Clin Chem Cliii Biochem 19:165—168, 1981
23. MARIN-GREZ M, SCHAECHTELIN G: The measurement of amido-
lytic activity in kidney homogenates for the estimation of renal
kallikrein. Kidney mt 22:697—701, 1982
24. BONNER G, AUTENRIETH R, MARIN-GREZ M, SPECK G, GROSS F:
Steroid induced changes of the renal kallikrein kinin system in rats.
Acta Endocrinol 107:131—140, 1984
25. NUSTAD K, PIERCE JV: Purification of rat urinary kallikreins and
their specific antibody. Biochem 13:23 12—2319, 1974
26. SUSTARSIC DL, MCPARTLAND RP, RAPP JP: Total and kallikrein
arginine esterase activities in the urine of salt-hypertensive Suscep-
tible and resistant rats. Hypertension 2:813—820, 1984
27. AMUNDSEN E, POTTER J, FIBERGER P. KNOS M, LARSBRATEN M,
CLAE5ON G: Methods for the determination of glandular kallikrein
128 Gross et a!: Lithium reduces kallikrein excretion
by means of a chromogenin-tripeptide, Adv Exp Med Biol 120A:
83—95, 1979
28. MANN K, GORING W, LiPP W, KEIPERT B, KARL HJ, GEIGER R,
FINK E: Radioimmunoassay of human urinary kallikrein. J Clin
Chem Clin Biochem 18:395—401, 1980
29. MITAS JA, LEVY SB, HOLLE R, FRIGON RP, STONE RA: Urinary
kallikrein activity in the hypertension of renal parenchymal disease.
NEngi J Med 299:162—165, 1978
30. O'CONNOR DT, BARG AP, AMEND W, VINCENTI F: Urinary
kallikrein excretion after renal transplantation. Am J Med 73:
475—481, 1982
31. FEJES-TOTH G, ZAHAJSZKY T, FILEP J: Effect of vasopressin on
renal kallikrein excretion. Am J Physiol 239:F388—F392, 1980
32. N0DA Y, YAMADA K, IGIc R, ErwOs EG: Regulation of rat urinary
and renal kallikrein and prekallikrein by corticosteroids. Proc Nat!
Acad Sci USA 80:3059—3063, 1983
33. HORWITZ D, MARGOLIUS HS, KEISER HR: Effects of dietary
potassium and race on urinary excretion of kallildein and aldoste-
rone in man. J Clin Endocrinol Metab 47:296—299, 1978
34. BONNER 0, AUTENRIETH R, MARIN-GREZ M, RASCHER W, GROSS
F: Effects of sodium loading, desoxycorticosterone acetate, and
corticosterone on urinary kallikrein excretion. Hormone Res 14:
87—94, 1981
35. GROSS F, SCHLENKER A, KOEPPEN-HAGEMANN 1, GELARDI R,
SAUER H, BERG T, BONNER G: Lithium interferes with renal
kallikrein. Proc. 22nd Annual Meeting, The American Society of
Nephrology, Washington, D.C., Dec. 3—6, 1989, pp. 181A
36. SINGER I, ROTENBERG D, PUSCHETT JB: Lithium-induced nephro-
genic diabetes insipidus: In vivo and in vitro studies. J Clin Invest
51:1081—1091, 1972
37. BENDZ H: Kidney function in a selected lithium population. Acta
Psych Scand 72:451—463, 1985
38. ALBRECHT J, KAMPF D, MUELLER-OERLINGHAUSEN B: Renal
function and biopsy in patients on lithium therapy. Pharmakopsy-
chiatr 13:228—234, 1980
39. WALKER RG, Escorr M, BIRCHALL I, DOWLING JP, KINCAID-
SMITH P: Chronic progressive renal lesions induced by lithium.
Kidney mt 29:875—881, 1986
40. COLT EWD, KIMBRELL D, FIEVE RR: Renal impairment, hyper-
calcemia and lithium treatment. Am J Psychiatr 138:106—108, 1981
41. MURPHY DL, GOODWIN FK, BUNNEY NE: Aldosterone and so-
dium response to lithium administration in man. Lancet 2:458—460,
1969
42. MARTINEZ-MALDONADO M, STAVROULAKI-TSAPARA A, TSAPARAS
H, SUKI WN, EKNOYAN G: Renal effects of lithium administration
in rats: Alterations in water and electrolyte metabolism and the
response to vasopressin and cyclic adenosine monophosphate
during prolonged administration. J Lab Gun Med 86:445—461, 1975
43. BIRCH NJ, JENNER FA: The distribution of lithium and its effects on
the distribution and excretion of other ions in the rat. Brit J
Pharmacol 47:586—594, 1973
44. MILLER PD, DUBOVSKY SL, MCDONALD KM. KATZ FH, ROBERT-
SON GL, SCHRIER RW: Central, renal and adrenal effects of lithium
in man. Am J Med 66:797—803, 1979
45. N0RGAARD T, FAARUP P, HANSEN BB, KRISTENSEN AR, CHRIS-
TENSEN S: Correlation between distal nephron enzyme activity,
structure and function in rats during lithium and lithium plus
neuroleptic treatment. Renal Physiol 8:50—61, 1985
